JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 29 No. 1 33-38
© 1988 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarke, S. E.M.
Right arrow Articles by Maisey, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarke, S. E.M.
Right arrow Articles by Maisey, M. N.

Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP-An Evaluation of Three Imaging Techniques in Patients with Medullary Carcinoma of the Thyroid

Susan E.M. Clarke, Colin R. Lazarus, Philip Wraight, Charles Sampson and Michael N. Maisey

Department of Nuclear Medicine, Guy's Hospital, London
Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, England

Correspondence: For reprints contact: Susan E.M. Clarke, MD, Dept. of Nuclear Medicine, Guy's Hospital, St Thomas St., London, SE1 9RT.

ABSTRACT

Nine patients with histologically proven medullary carcinoma of the thyroid (MCT) were imaged using pentavalent [99mTc]dimercaptosuccinic acid [(V)DMSA], [131I] metaiodobenzylguanidine (MIBG) and [99mTc]methylene diphosphonate (MDP). Technetium-99m (V)DMSA demonstrated most of the tumor sites in eight patients with proven metastases, with an overall sensitivity of 95% in lesion detection. Iodine-131 MIBG showed definite uptake in some of the tumor sites in three of the nine patients imaged, with equivocal uptake seen in a further one patient, with sensitivity of only 11% for lesion detection. Technetium-99m MDP demonstrated bony metastases only, in four of the patients imaged yielding a sensitivity of 61%. Technetium-99m (V)DMSA has been demonstrated in this study to be a useful imaging agent in patients with MCT, showing uptake in significantly more lesions and with better imaging qualities than [131I]MIBG, and with the ability to detect soft tissue as well as bony metastases.




This article has been cited by other articles:


Home page
ImagingHome page
S E M Clarke and S C Rankin
The thyroid gland
Imaging, April 1, 2002; 14(2): 103 - 114.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
B.-F. Lee, N.-T. Chiu, D.-C. Wu, K.-B. Tsai, G.-C. Liu, H.-S. Yu, and S.-T. Wang
Use of 99mTc (V) DMSA Scintigraphy in the Detection and Localization of Intestinal Inflammation: Comparison of Findings at Colonoscopy and Biopsy
Radiology, August 1, 2001; 220(2): 381 - 385.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1988 by the Society of Nuclear Medicine.